Sugi Predict

Sugi Predict / Compounds / SCHEMBL14738374

SCHEMBL14738374

SCHEMBL14738374

COC(C)CNC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.44
▸ CA2 P00918 2/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CTSS P25774 3/20 0.42
▸ CTSK P43235 3/20 0.42
▸ CTSL P07711 1/20 0.42
▸ CTSB P07858 1/20 0.42
▸ CA12 O43570 2/20 0.40
▸ CA14 Q9ULX7 2/20 0.40
▸ SYK P43405 1/20 0.40
▸ SERPINE1 P05121 1/20 0.40
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ PCSK9 Q8NBP7 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3161149 1.00 MEN1 (0.46) MEN1GAAKMT2ATDP1CA2
SCHEMBL3157438 1.00 MEN1 (0.46) MEN1GAAKMT2ATDP1CA2
SCHEMBL14296201 0.85 MEN1 (0.50) MEN1GAAKMT2ATDP1CA2
SCHEMBL10463299 0.83 MEN1 (0.45) MEN1GAAKMT2ATDP1CA2
SCHEMBL21937384 0.83 MEN1 (0.45) MEN1GAAKMT2ATDP1CA2
SCHEMBL18508254 0.83 MEN1 (0.45) MEN1GAAKMT2ATDP1CA2
SCHEMBL6131611 0.82 MEN1 (0.47) MEN1GAAKMT2ATDP1CA2
SCHEMBL12143608 0.82 MEN1 (0.47) MEN1GAAKMT2ATDP1CA2
SCHEMBL1105702 0.82 PCSK9 (0.50) MEN1GAAKMT2ATDP1CA2
SCHEMBL6563149 0.82 MEN1 (0.50) MEN1GAAKMT2ATDP1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024019957-A1 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CELGENE CORPORATION (US) 2024-01-25 — — WO disclosed
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 — — US disclosed
WO-2020117626-A1 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS MERCK SHARP & DOHME CORP. (US) 2020-06-11 — — WO disclosed
EP-2931316-B1 HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES MERSANA THERAPEUTICS INC (US) 2019-02-20 — — EP disclosed
US-20170348424-A1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2017-12-07 — — US disclosed
US-9770519-B2 Protein-polymer-drug conjugates MERSANA THERAPEUTICS, INC. (US) 2017-09-26 — — US disclosed
US-20170119896-A1 TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF MERSANA THERAPEUTICS, INC. 2017-05-04 — — US disclosed
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 — — EP disclosed
US-20160067353-A1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2016-03-10 — — US disclosed
US-20150306240-A1 HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES MERSANA THERAPEUTICS, INC. 2015-10-29 — — US disclosed
US-8815226-B2 Protein-polymer-drug conjugates MERSANA THERAPEUTICS, INC. (US) 2014-08-26 — — US disclosed
US-8808679-B2 Auristatin compounds and conjugates thereof MERSANA THERAPEUTICS, INC. (US) 2014-08-19 — — US disclosed
EP-2763990-A1 PYRROLOPYRAZINE KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-08-13 — — EP disclosed
WO-2014093640-A1 HYDROXY-POLMER-DRUG-PROTEIN CONJUGATES MERSANA THERAPEUTICS,INC. (US) 2014-06-19 — — WO disclosed
US-20140134127-A1 Protein-Polymer-Drug Conjugates MERSANA THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 — — US disclosed
US-20140017265-A1 Terminally Modified Polymers and Conjugates Thereof MERSANA THERAPEUTICS, INC. 2014-01-16 — — US disclosed
US-20130101546-A1 Protein-Polymer-Drug Conjugates MERSANA THERAPEUTICS, INC. (US) 2013-04-25 — — US disclosed
WO-2013030138-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 — — WO disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348424-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, CLTB, BRAP MEN1 4707/4885GAA 1351/4885KMT2A 2203/4885
US-20140134127-A1 Protein-Polymer-Drug Conjugates PBRM1, CLTB, BRAP MEN1 4707/4885GAA 1351/4885KMT2A 2203/4885
US-20140017265-A1 Terminally Modified Polymers and Conjugates Thereof MALT1, ALG1, PRMT3 MEN1 1055/4885GAA 1601/4885KMT2A 1139/4885
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, BCL9, CRBN MEN1 3371/4885GAA 2228/4885KMT2A 727/4885
US-20160067353-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, CLTB, BRAP MEN1 4707/4885GAA 1351/4885KMT2A 2203/4885
US-20150306240-A1 HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES PBRM1, HDGFL3, CLTB MEN1 4802/4885GAA 2114/4885KMT2A 1568/4885
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK1 MEN1 3956/4885GAA 2745/4885KMT2A 1627/4885
US-20170119896-A1 TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF MALT1, ALG1, PRMT3 MEN1 1055/4885GAA 1601/4885KMT2A 1139/4885
US-20130101546-A1 Protein-Polymer-Drug Conjugates PBRM1, CLTB, BRAP MEN1 4727/4885GAA 1493/4885KMT2A 1978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.